APPLICATION
Application Note
The peptide is used for blocking the activity of anti-DcR1 (GTX25975). Incubating the peptide with equal volume of antibody for 30 min at 37ºC usually completely blocks the antibody activity in Western blotting.
PROPERTIES
Form
Liquid
Buffer
PBS, 0.1% BSA
Preservative
0.02% Sodium azide
Storage
Store the peptide at -20ºC, stable for one year.
Concentration
0.20 mg/ml (Please refer to the vial label for the specific concentration.)
Conjugation
Unconjugated
Note
For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.
TARGET
Synonyms
Tnf Receptor Superfamily Member 10C , Cd263 , Dcr1 , Dcr1-Tnfr , Lit , Trail-R3 , Trailr3 , Trid , Tnfrsf10C
Background
Apoptosis is induced by certain cytokines including TNF and Fas ligand in the TNF family through their death domain containing receptors. TRAIL/Apo2L is a new member of the TNF family and induces apoptosis of a variety of tumor cell lines. DR4 and DR5 are the recently identified functional receptors for TRAIL. Two decoy receptors for TRAIL have been identified and designated DcR1/TRID/TRAILR3/ LIT and DcR2/TRAIL-R4/TRUNDD. DcR1 has extracellular TRAIL-binding domain but lacks intracellular signaling domain. It is a glycophospholipid anchored cell surface protein. DcR1 transcripts were expressed in many normal human tissues but not in most cancer cell lines. Overexpression of DcR1 did not induce apoptosis, but attenuated TRAIL-induced apoptosis.
Research Area
REFERENCE
There are currently no references for DcR1 peptide (GTX27880). Be the first to share your publications with this product.
REVIEW
There are currently no reviews for DcR1 peptide (GTX27880). Be the first to share your experience with this product.